https://www.medscape.com/viewarticle/907353
Jan 8th, 2019 - Postmenopausal women who experience persistent hot flashes are more likely to be diagnosed with breast cancer than women who never experience vasomotor symptoms (VMS), but they are not more likely to die from it, a new long-term analysis from the Women's Health Initiative (WHI) suggests. At a median follow-up of 17.9 years, women who reported having persistent VMS fo...
https://www.medpagetoday.com/endocrinology/generalendocrinology/77266
Jan 4th, 2019 - U.S. News & World Report put the Mediterranean diet at the top of its annual nutrition ranking, followed by a tie between the DASH and Flexitarian diets for second place. Finnish researchers found that men who ate one egg every day had reduced risk for type 2 diabetes. "Although it is too early to draw any causal conclusions, we now have some hints about certain egg-related compounds tha...
https://www.ncbi.nlm.nih.gov/pubmed/30601454
Menopause (New York, N.Y.); Chlebowski RT, Mortimer JE et. al.
Dec 28th, 2018 - Vasomotor symptoms (VMS) including hot flashes and night sweats are common during the menopausal transition and may persist. Although VMS pathophysiology is complex, estrogen's efficiency as VMS therapy suggests hormonal environment change may influence this process. As studies of VMS and breast cancerare inconsistent, we examined associations between persistent VMS...
https://www.medpagetoday.com/obgyn/hrt/77132
Dec 27th, 2018 - Action Points Long-term follow-up of systemic-hormone-therapy-naive, postmenopausal women found that vaginal estrogen use was not associated with a greater risk of cardiovascular disease or cancer. Findings lend support to the supposition that low-dose, vaginal estrogen is safe for genitourinary syndrome of menopause (GSM). CME Author: Zeena Nackerdien Study Authors: Shilpa N. Bhu...
https://www.medscape.com/viewarticle/906249
Dec 10th, 2018 - SAN ANTONIO — Oxybutynin (multiple brands), an anticholinergic widely used to treat urinary incontinence caused by an overactive bladder, is surprisingly effective in the treatment of hot flashes in breast cancer survivors, new research shows. It was also effective in study patients who did not have breast cancerbut who were bothered by frequent or sev...
https://www.mdedge.com/obgyn/article/190618/breast-cancer/tamoxifen-5-mg-halves-recurrence-breast-intraepithelial-neoplasia
Neil Osterweil
Dec 7th, 2018 - SAN ANTONIO – Good old tamoxifen, there's life in the old girl yet: A 3-year course of low-dose tamoxifen – one-fourth of the standard dose – reduced the risk of breast intraepithelial neoplasia (IEN) recurrence by half, compared with placebo. And although the patient numbers were relatively small, tamoxifen at 5 mg/day also reduced the risk of contralateral breast.
https://emedicine.medscape.com/article/1762071-overview
Dec 7th, 2018 - Practice Essentials Systemic tamoxifen has been the standard approach for reducing risk of recurrence in women with estrogen receptor (ER)–positive early-stage breast cancer for more than 40 years. Long-term data have demonstrated that the use of tamoxifen reduces recurrence and mortality by more than 30% in both premenopausal and postmenopausal women, regardless of the use of sys...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20910750-2bb6-4258-8368-df9ec207bfdd
Oct 31st, 2018 - Recent Major Changes Section Dosage and Administration (2.2) 10/2015 Warnings and Precautions (5.3, 5.4,5.7, 5.8, 5.9) 10/2015 Boxed Warning Section Anaphylactic reactions to oxaliplatin injection have been reported, and may occur within minutes of oxaliplatin injection administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms of anaphylaxis [se...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8efb4c07-455b-4c91-b257-6fd43854454c
Oct 25th, 2018 - Recent Major Changes Section DOSAGE AND ADMINISTRATION (2.2) 12/2011 WARNINGS AND PRECAUTIONS (5.1, 5.2) 12/2011 Boxed Warning Section Anaphylactic reactions to oxaliplatin for injection have been reported, and may occur within minutes of oxaliplatin for injection administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms of anaphylaxis [see Wa...
https://www.ncbi.nlm.nih.gov/pubmed/30239824
Journal of the National Cancer Institute; Wheeler SB, Spencer J et. al.
Sep 20th, 2018 - Differential use of endocrine therapy (ET) by race may contribute to breast cancer outcome disparities, but racial differences in ET behaviors are poorly understood. Women aged 20-74 years with a first primary, stage I-III, hormone receptor-positive (HR+) breast cancer were included. At 2 years postdiagnosis, we assessed nonadherence, defined as not taking ET every d...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44c89f9c-2194-4d33-9bde-f8f309d33ef2
Sep 10th, 2018 - Recent Major Changes Section Contraindications, Pregnancy (4.2) 06/2018 Warnings and Precautions, Premenopausal Use (5.4) 06/2018 Boxed Warning Section Increased risk of deep vein thrombosis and pulmonary embolism have been reported with raloxifene hydrochloride [see Warnings and Precautions (5.1)]. Women with active or past history of venous thromboembolism should not take ...
https://www.medpagetoday.com/obgyn/menopause/74851
Aug 30th, 2018 - Chemotherapy as part of lung cancer treatment was associated with early-onset menopause in younger women, researchers reported. In an analysis of premenopausal women who were diagnosed with lung cancer before the age of 50, 64% of women who received chemotherapy said they began menopause during the year post-diagnosis, according to Elizabeth Cathcart-Rake, MD, of the Mayo Clinic i...
https://www.mdedge.com/obgyn/article/190516/breast-cancer/low-dose-tamoxifen-halves-recurrence-breast-intraepithelial
Neil Osterweil
Mar 30th, 2018 - SAN ANTONIO – New life for old medicine: Women aged under 75 years with breast intraepithelial neoplasms (IEN) who took tamoxifen for 3 years at a dose of 5 mg per day – one-fourth the standard dose – had a 50% reduction in risk of IEN recurrence and an even more remarkable 75% reduction in the risk of contralateral breast cancer, compared with women who took.
https://www.medscape.com/viewarticle/894365
Mar 28th, 2018 - With the national crisis of opioid abuse focusing attention on nonpharmaceutical pain relief, new data on acupuncture has oncologists taking a deeper look at this complementary therapy. Most recently, another phase 3 trial, Southwest Oncology Group (SWOG) S1200, has shown that acupuncture is a viable alternative to medication to relieve symptoms related to cancer and cancer treatm...
https://www.ncbi.nlm.nih.gov/pubmed/29548486
Critical Reviews in Oncology/hematology; Angioli R, Luvero D et. al.
Mar 20th, 2018 - As growing of old women population, menopausal women will also increase: an accurate estimation of postmenopausal population is an essential information for health care providers considering that with aging, the incidence of all cancers is expected to increase. Hormone replacement therapy (HRT) has proven to be highly effective in alleviating menopausal symptoms such as hot fla...
https://www.mdedge.com/familypracticenews/article/159768/womens-health/abstract-please-dont-give-hormone-therapy-d
Mar 2nd, 2018 - Pinkerton, J. V.
https://www.mdedge.com/psychiatry/article/159107/schizophrenia-other-psychotic-disorders/decompensation-51-year-old-woman/page/0/2
Mar 1st, 2018 - Given estrogen's potentially protective effects, clinical trials have explored the role of estrogen as an adjuvant to antipsychotics for treating schizophrenia. Studies have shown that estrogen can improve psychotic symptoms in patients with schizophrenia.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22c7652a-aa16-4fa8-89d9-517e69059068
Feb 20th, 2018 - Boxed Warning Section Addiction, Abuse, and Misuse Oxymorphone Hydrochloride Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing OXYMORPHONE HYDROCHLORIDE TABLETS and monitor all patients regularly for the development of these behaviors and conditions [see Warnings and...
https://www.ncbi.nlm.nih.gov/pubmed/29404595
Annals of Internal Medicine; Reynolds EE, Bates C et. al.
Feb 7th, 2018 - Hormone therapy (HT) was widely prescribed in the 1980s and 1990s and has been controversial since the initial results of the Women's Health Initiative (WHI) trial in the early 2000s suggested that it increased risk for breast cancer and coronary heart disease and did not prolong life. However, more recent data and reexamination of the WHI results suggest that HT is safe an...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου